𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders

✍ Scribed by M. Fiegl; G. Gastl; G. Hopfinger; K. Eigenberger; A. Zabernigg; T. Schenk; F. Falkner; A. Falkner; S. Sodia; M. Doubek; Y. Brychtova; A. Panovska; R. Greil; J. Mayer; for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukaemia, in cooperation with The Czech Leukemia Study Group for Life, CELL

Book ID
107636633
Publisher
Springer-Verlag
Year
2008
Tongue
English
Weight
251 KB
Volume
1
Category
Article
ISSN
1865-5041

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of alemtuzumab in chronic
Phase II study of alemtuzumab in chronic lymphoproliferative disorders
✍ Alessandra Ferrajoli; Susan M. O'Brien; Jorge E. Cortes; Francis J. Giles; Debor πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 82 KB

## Abstract ## BACKGROUND Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders. ## METHODS Seventy‐eight patients